US6258385B1

Extracted document text. Layout, formulas and symbols may not survive extraction; consult the preserved PDF for the original presentation.

Text extraction covers 5 pages, including 5 transcribed by optical character recognition.

Page 1

(2)

United States Patent

Antelman

US!

US 6,258,385 Bl
Jul. 10, 2001

(006258385B1

(10) Patent No.:
(45) Date of Patent:

G64)

(75)
(73)

@)

@1)

(22)

(63)
G1)
62)

G8)

G6)

TETRASILVER TETROXIDE TREATMENT
FOR SKIN CONDITIONS

Inventor: Marvin S. Antelman, Pehovot (IL)

Assignee: Marantech Holding, LLC, Providence,
RI (US)

Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

US.C. 154(b) by 0 days.

Appl. No.: 09/552,172
Filed: Apr. 18, 2000

Related U.S. Application Data

Continuation-in-part of application No. 09/296,998, filed on
Apr. 22, 1999, now abandoned.

Int. Cl.” ... AGIK 33/38; A61K 9/00

US. Cl. . 424/618, 424/405; 424/439;

514/859; 514/861; 514/863; 514/925, 514/928;

514/931; 514/934; 514/937, 514/938; 514/969

Field of Search . .. 424/405, 489,

424/618; 514/859, 861, 863, 925, 928,

931, 934, 937, 938, 969

References Cited
U.S. PATENT DOCUMENTS,

4,828,832 *
5,017,295
5,073,382
5,078,902
5,089,275
5,098,582
5,211,855
5,223,149

5/1989
5/1991
12/1991
1/1992
2/1992
3/1992
5/1993
6/1993

De Cuellar et al.
Antelman
Antelman
Antelman
Antelman
Antelman
Antelman
Antelman

424/618
210/764
424/604
210/764
424/602
210/759
210/758
210/764

5,334,588 * 8/1994 Fox, J .. S14/171
5,336,416 8/1994 Antelman 210/764
5,336,499 8/1994 Antelman 424/405
5,571,520 * 11/1996 Antelman 424/405
5,676,977 10/1997 Antelman 424/618
5,772,896 6/1998 Denkewicz, Jr. et al. 210/754

OTHER PUBLICATIONS

The Merck Manual (16th Ed. 1992), ‘Dermatologic Disor-
ders’, pp. 2399-2460.*

Dorland’s Illustrated Medical Dictionary (28th Ed. 1994),
pp. 351,759-60.*

Remington’s Pharmaceutical Sciences (17th Ed. 1985), pp.
1573-1575, 1585-1602.*

Antelman, Marvin S.; “Silver (ILI) Disinfectants”; Soap/
Cosmetics/Chemical Specialties, Mar. 1994, pp. 52-59.
Antelman, Marvin S.; Abstracts of the American Chemical
Society, 1992(203).

Antelman, Marvin S.; “Anti-Pathogenic Multivalent Silver
Molecular Semiconductors”; Precious Metals; 1992(16); pp.
141-149.

Antelman, Marvin S.; “Multivalent Silver Bactericides”;
Precious Metals; 1992(16); pp. 151-163.

* cited by examiner

Primary Examiner—Jose’ G. Dees
Assistant Examiner—Frank Choi
(74) Attorney, Agent, or Firm—Pennie & Edmonds LLP

(57) ABSTRACT

The invention relates to the use of electron active molecular
crystals comprising tetrasilver tetroxide (Ag,O,) for the
treatment and cure of dermatological skin conditions
(diseases) ranging from dermatitis, acne and psoiasis to
herpes and skin ulcers.

20 Claims, No Drawings

Page 2

US 6,258,385 B1

1

TETRASILVER TETROXIDE TREATMENT
FOR SKIN CONDITIONS

This Application is a Continuation-In-Part of application
Ser. No. 09/296,998, filed Apr. 22, 1999, now abandoned.

BACKGROUND OF THE INVENTION

The present invention relates to the use of electron active
molecular crystals comprising tetrasilver tetroxide (Ag,O.,)
for the treatment and cure of dermatological conditions or
diseases.

The present invention is related to concepts previously
elucidated and disclosed in U.S. Pat. No. 5,336,499 (1994);
USS. Pat. No. 5,571,520 (1996) and U.S. Pat. No. 5,676,977
(1997). Said concepts have also been published in an article
entitled “Silver (II, II) Disenfectants” (Soap/Cosmetics/
Chemical Specialties, 1994; March, pp. 52-59).

The aforementioned references disclose that said tetrasil-
ver tetroxide devices kill and/or inhibit a wide variety of
pathogens ranging from gram positive and negative bacteria
(e.g., E coli and Staphylococcus aureus), algae and mold
(e.g., Chorella and Candida albicans) and the AIDS virus.
Said references also contain detailed descriptions of the
mechanism via which said molecular crystal devices oper-
ate. The instant inventor also presented his subsequent
results and concepts at a Seminar entitled “Incurable Dis-
eases Update” (Weizmann Institute of Science, Rehovot,
Israel, Feb. 11, 1998). The title of his presentation was
“Beyond Antibiotics, Non Toxic Disinfectants and Tetrasil
Mademark of applicant for the tetroxide)”.

In the aforecited article it was shown that the effects of the
electron transfer involved with respect to the tetroxide,
phenomenally, rendered it a more powerful germicide than
other silver entities. The instant inventor holds patents for
multivalent silver anti microbials, e.g., U.S. Pat. No. 5,017,
295 for Ag(II) and U.S. Pat. No. 5,223,149 for Ag (III); and
while these entities are stronger anti microbials than Ag (1)
compounds they pale by comparison to the tetroxide and so
does colloidal silver which derives its germicidal properties
from trace silver (I) ions it generates in various environ-
ments. Accordingly, the oligodynamic properties of these
entities may be summarized as follows, which is referred to
as the Horsfal series:

Ag,O,>Ag(III)>Ag(ID)>>>>Ag(1)

The other unique property of the tetroxide was that it did
not stain organic matter such as skin in like manner as Ag(I)
compounds do. In addition, it was light stable.

The main object of this invention is to utilize tetrasilver
tetroxide molecular devices to cure dermatological diseases
or conditions.

Another object of this invention is to use tetrasilver
tetroxide molecular devices to control those dermatological
conditions or diseases which cannot be cured completely by
said devices.

Still another object of this invention is to use tetrasilver
tetroxide molecular devices to reduce the time of affliction
of dermatological conditions or diseases.

Still another object of this invention is to utilize said
devices in the aforesaid dermatological applications without
staining the skin.

SUMMARY OF THE INVENTION

This invention relates to a molecular scale device com-
prising a single crystal of tetrasilver tetroxide (Ag,O,).

20

30

40

50

60

2

Several trillion of these molecules may be employed in
various pharmaceutical formulations and therapies to effec-
tuate the treatment and cure of various dermatological
conditions and diseases. These conditions and diseases vary
and include eczema, psoriasis, dermatitis, disease induced
skin ulcers, undefined tropical diseases, shingles, rashes,
bedsores, cold sores, blisters, boils, herpes simplex, acne,
pimples, skin chafing, cracking, itchiness, skin peeling, and
warts.

More particularly, the invention relates to a method for
treating dermatological skin disease comprising applying a
composition comprising tetrasilver tetroxide directly to the
affected skin areas, said composition being free of added
oxidizing agent.

Even more particularly, the invention relates to a method
for treating dermatological skin conditions selected from the
group consisting of eczema, psoriasis, dermatitis, ulcers,
shingles, rashes, bedsores, cold sores, blisters, boils, herpes,
acne, pimples, skin chafing, cracking, skin itch, skin peeling
and warts comprising applying tetrasilver tetroxide directly
to the affected skin area.

DESCRIPTION OF THE INVENTION

The crystal lattice of the Ag,O,, molecular device operates
against pathogens by transferring electrons from its two
monovalent silver ions to the two trivalent silver ions in the
crystal contributing to the death of pathogens by traversing
their cell membrane surface. This in effect “electrocutes” the
pathogens. The electrons are forced out of their balanced
crystals by such labile groups as NH, NH,, S—S and SH
comprising pathogen cell membrane surface. However, nor-
mal cells will not be affected because they do not proliferate
fast enough to expose these labile bonds.

The K, of Ag,O, is 7.9x10-'%, therefore the molecule
will not be disturbed unless more stable complexes are
formed with such ligands as those comprising the pathogen
cell membrane surface in a dynamic state. Indeed the end
result of the electron transfer, which is a redox reaction,
results in the monovalent Ag ions being oxidized to Ag(II)
and the trivalent Ag ions being reduced to the same end
product, Ag(II). Accordingly, the well-known affinity for
monovalent silver for certain elements such as sulfur and
nitrogen is far exceeded here, for divalent silver will not
merely bind to these elements as does silver, but will
actually form chelate complexes with their ligands. The
molecular crystal attraction for the cell membrane surfaces
is thus driven by powerful covalent bonding forces.

The electron transfer can be depicted by the following
redox half reactions:

‘Ag’ —e = Ag?

Ag? +e=Ag?

It was found by rigorous testing that silver tetroxide was
comparatively non toxic. Since said oxide was effective at
PPM concentrations in killing pathogens, commercial con-
centrates were formulated with 2% of the tetroxide. For
acceptance of said oxide in commerce for which an EPA
registration number was obtained (no. 3432-64), it was
necessary for the oxide to undergo a series of toxicity tests,
for which a 3% concentrate was used and evaluated by a
certified laboratory employing good laboratory practice
(GLP) according to the Code of Federal Regulations.

Page 3

US 6,258,385 B1

3

The results were as follows:

Acute Oral Toxicity
Acute Dermal Toxicity
Primary Eye Irritation
Primary Skia Irritation
Skin Sensitization

LDso Greater than 5,000 mg/Kg.
LD5o Greater than 2,000 mg,/Kg.
Mildly irritating

No irtitation

Non Sensitizing

Subsequent evaluations showed that unless persons were
prone to silver allergies, the pure tetroxide could be applied
to the skin without any ill effects or evidence of irritation,
despite the fact that said oxide is a powerful oxidizing agent.
This can perhaps be explained by its stability manifested by
its aforecited K,.

It was previously postulated in earlier patents relating to
the various uses of the oxide that it was required to use it in
combination with an excess of strong oxidizing agent such
as a persulfate in order to effectively kill pathogens.
However, the additional presence of oxidizing agent tends to
be irritating to the skin. It has been found in accordance with
the present invention that the additional oxide is unnecessary
and in fact undesirable for the purpose of treating the skin
diseases described herein. Therefore, the present invention
contemplates application of the oxide to the skin in the
absence of the additional oxidizer and the use of formula-
tions which are free of added additional oxidizing agent such
as a persulfate.

A preferred mode of application of the oxide of the
invention is as a topical agent, either directly as a powder or
in non-sprayable or sprayable form. Non-sprayable forms
can be semi-solid or solid forms comprising a carrier indig-
enous to topical application and having a dynamic viscosity
preferably greater than that of water. Suitable formulations
include, but are not limited to, suspensions, emulsions,
creams, ointments, powders, liniments, salves and the like.
Tf desired, these may be sterilized or mixed with auxiliary
agents, ¢.g., thixotropes, stabilizers, wetting agents, and the
like. Preferred vehicles for non-sprayable topical prepara-
tions include ointment bases, e.g., polyethylene glycol-1000
(PEG-1000); conventional ophthalmic vehicles; creams; and
gels, as well as petroleum jelly and the like. These topical
preparations may also contain emollients, perfumes and/or
pigments to enhance their acceptability for various usages.

Where the oxide is applied to the skin combined with a
carrier such one or more of the carriers described above, it
may be combined with the carrier at a level of from about 50
to 250,000 PPM, more preferably from about 400 to 50,000
PPM, based on the weight of the carrier, and applied to the
skin 1 to 3 times per day until the condition is cured or
satisfactorily controlled. Generally, the composition may be
applied at a dosage level of from about 10 to 500 mg per em?
of skin surface.

Accordingly, the oxide was used directly in powder form
as well as in several compounded formulations for treating
a wide assortment of skin conditions and diseases. Success
was achieved in all cases except for certain stubborn nail
fungi. After much experimenting it was found that the best
carrier for a commercial product was white petroleum jelly.

Other objects and features of the present invention shall
become apparent to those skilled in the art when the present
invention is considered in view of the accompanying
examples. It should, of course, be recognized that the
accompanying examples illustrate preferred embodiments of
the present invention.

EXAMPLE 1

A female, age 28, resident of Central America, had a red
rash caused by an unidentified dermatological tropical dis-

15

20

30

40

66

4

ease on her thigh. The condition was cured by a light dusting
of Ag,O., crystals on the area. Similar occurrences in the
past to the subject failed to be cured by other dermatological
preparation sold as cures for said condition.

EXAMPLE 2

A female, age 27, had a fungus infection in her navel. She
was cured by direct application of Ag,O, to the affected area
within 24 hours.

EXAMPLE 3

A female in her early thirties had suffered from recurrent
cold sores for five years. The subject stated in a written
communication, “I have tried every over-the-counter medi-
cation for this ailment without even marginal success. I even
tried the five times a day for five days herpes medication that
my doctor prescribed with disappointing results.” Subject
tried various concentration of Ag,,O, dispersed in petroleum
jelly. All formulation improved the severity and duration of
the herpes simplex. Subject was given a final formulation of
10,000 PPM Ag.,O, dispersed in white petroleum jelly. In
many instances quick application of the ointment resulted in
disappearance of the cold sore the next day. Otherwise if not
caught quickly the sore could be contained within 36 hours
which was a vast improvement over the previous treatments.

EXAMPLE 4

An 82-year-old female had suffered six months from an
external vaginal itch which defied treatment. Application of
Ag,O, ointment (as described in Example 3) cured the
condition.

EXAMPLE 5

‘Twenty-two samples of Ag,O, ointment were distributed
to individuals who were suffering from the herpes simplex.
They all applied the ointment. While there was no attempt
made to record the exact condition of the herpes subjects, all
22 cases were cured within 48 hours.

EXAMPLE 6

Having achieved success against herpes simplex, it was
decided to test Ag,O, ointment against shingles which is
caused by herpes zoster. Accordingly, a 67-year-old male
applied the ointment three times a day for two days, after
which time the shingles condition was completely gone.

EXAMPLE 7

‘Two individuals, one male, the other female, ages 33 and
48, who were suffering from external acne condition, treated
their skin three times a day with Ag,O, ointment. They were
completely cured after two days of applying the ointment.

EXAMPLE 8

Fifteen patients with an age ranging from 30 to 35 which
were diagnosed as having oral viral herpes were arranged in
two groups. Group I consisted of five patients which suffered
from severe oral viral outbreaks with a recurring frequency
of 21-28 days. The sizes of the herpes sores ranged from
3.5-5.0 mm. Group II consisted of ten patients who suffered
from normal oral viral outbreaks with a recurring frequency
of 28-42 days. The sizes of the herpes sores ranged from
1.25-1.75 mm. Both groups applied tetrasilver tetroxide
ointment to the effected areas with 50-200 mg. of ointment
containing 3% tetrasilver tetroxide. Group I applied the

Page 4

US 6,258,385 B1

5

ointment (within 12 hrs.) after the herpes sores broke
through the skin and blistered. Group II was divided into two
subgroups. Group ITA applied the ointment (within 12 hrs.)
after the herpes sores broke through the ski and blistered.
Group IIB applied the ointment 4—12 hrs. before the herpes
sores broke through the skin and blistered. Application was
twice daily. Patients reported daily on the pharmacological
effects. Sizes of the herpes growth were observed on a daily
basis for five days and frequency of reoccurrence was
recorded.

Summary of Results

Group I: Over a period of 24-48 hours all of the patients
observed the herpes sore regress and dry out. By day three
the sores were not visible and the skin was healed. All
patients exhibited a longer recurrence time from 32-44 days
excluding one patient who did not have a recurrence for
eight months. The sizes of the herpes upon recurrence were
significantly smaller at 2.2-3.5 mm.

Group IIA: Over a period of 24-48 hours all the patients
observed the herpes sore regress and dry out. By the end of
day the sores were not visible and the skin was healed. All
patients exhibited a longer recurrence time from 34-55 days.
The sizes of the herpes upon reoccurrence were significantly
smaller at 0.8-1.4 mm.

Group IIB: Over a period of 12-24 hours all the patients
observed that the herpes sore was retained and never broke
through the skin as a blister. By the end of day two there
were no signs of the herpes sore at all. There was not even
the slightest amount of discomfort around the area where the
blisters would have flourished. All patients exhibited a
longer recurrence time from 36-62 days. The sizes of the
herpes upon recurrence were 0.7-1.6 mm.

Conclusions
Tetrasilver tetroxide used as a topological ointment:

1. Eliminates oral viral herpes sores within a period of 48

hours from the time of the first application.

2. Extends the recurrence period of the viral herpes
breakout cycle.

3. Prevents the herpes virus from breaking through the
skin when used before an outbreak occurs.

EXAMPLE 9

Twenty eight patients in the age group ranging from 45 to
65 presenting with diabetes—induced foot ulcers were
arranged in two groups. All of the patients were taking
insulin injections and were diagnosed as Type I insulin
dependent.

Group I consisted of fourteen patients where culture
swabs of the ulcerated skin indicated the presence of bac-
teria (infection). Group II consisted of fourteen patients
where culture swabs of the ulcerated skin did not indicate the
presence of abnormal amounts of bacteria, (no infection).

The patients in each group were treated by applying 200
mg of a petroleum jelly containing 3 wt % tetrasilver
tetronide twice daily to the ulcerated sores for a 30 day
period. Daily evaluations of the skin condition were con-
ducted by a dermatologist.

Summary of Results

Group I: Within 48 hours of the onset of treatment the
sores on the feet of all patients began to dry out. After 72
hours, the ulcers on all patients started to heal at the borders.
By the fourth day, inflammation of the diseased tissue eased
and by the sixth day the ulcers were completely dry with no
surface secretions. By the tenth day the ulcers on all patients
had completely disappeared. Lab tests indicated no sign of
infection on the feet of any patient.

10

20

30

40

60

6

Group II: Within 24 hours of the onset of treatment the
sores on the feet of all patients began to dry out and heal at
the borders with no secretion. By the third day the sores on
all patients were covered with new healthy tissue. By the
tenth day the ulcers had healed and completed the process of
forming scar tissue by 80%. At day 14 of the treatment all
of the ulcers were 100% healed with no sign of infection.

Continuous monitoring of both groups over the 30 day
period indicated no reappearance of the ulcers.

The above testes demonstrate that tetrasilver tetroxide
treatment is effective in both curing infections associated
with diabetes-induced ulcers and in healing the ulcers them-
selves. The tetroxide accelerated the neovascularization’
process of the affected tissue.

EXAMPLE 10

Twenty patients ranging from age 8 months to 12 years
were clinically diagnosed as suffering from atopic dermatitis
involving inflamed lesions of the face and extremities, but
without bacterial involvement. These patients were previ-
ously treated by the application of topical steroids to the
affected skin areas, which was discontinued. The patients
were divided into two groups.

Group I consisted of ten randomly selected patients. A
petroleum jelly containing 3 wt % tetrasilver tetroxide was
applied at a dosage of about 100 mg. to all affected skin
areas of each patient twice daily for a period of days. Daily
evaluation of the skin condition was made by a dermatolo-
gist.

Group II consisted of a control group comprising, the
remaining ten patients. This group was treated by twice daily
application of about 100 mg of pure petroleum jelly which
was free of added tetrasilver tetroxide to the affected skin
areas.

Summary of Results

Group I: Within 12 hours of the onset of treatment the
lesions on all patients began to show healing and drying and
no longer exhibited prurito in the affected skin areas. Within
24 hours of the onset of treatment, signs of irritation of the
skin areas had subsided and after 24 hours signs of irritation
had disappeared and the lesions were no longer visible.
Treatment on all patients was discontinued after 5 days, but
the group was assessed daily for any recurrence of the
lesions. Two of the patients presented a reappearance of
lesions by the twenty-fourth day, but these lesions were
smaller and less irritating than the original lesions. Treat-
ment was resumed on these two patients and after 24 hours
the lesions had disappeared.

Group II: At 12 hours after the onset of the application of
pure petroleum jelly to the affected skin areas there were no
signs of improvement of the skin. Over the next 23 day
period the lesions gradually became more irritated with no
sign of healing of the atopic dermatitis.

The above tests demonstrate that the tetrasilver tetroxide
treatment is effective in most patients in healing atopic
dermatitis within 24 hours of the commencement of treat-
ment and appears to halt the self immunological reaction of
atopic dermatitis at the local level. It is also effective in
reversing disease when it recurs, increasing the period of
recession of the condition.

EXAMPLE 11

‘Twenty four patients between the ages of 13 and 40 years
were diagnosed as suffering from psoriasis, exhibiting
irritation, scaliness and both the Auspitz sign and the Koeb-
ner phenomenon. All patients had been previously treated
with topical steroids. The patients were divided into two
groups.

Page 5

US 6,258,385 B1

7

Group I consisted of 12 patients where psoriasis was
diagnosed less than 60 days prior to treatment A petroleum
jelly containing 3 wt % tetrasilver tetroxide was applied to
affected skin areas twice a day over a 30 day period and each
patient was evaluated twice daily by a dermatologist.

Group II consisted of 12 patients who were diagnosed
more than 60 days prior to treatment. Disease in this group
was more severe than Group I and most had been suffering
from psoriasis for many years, exhibiting extensive disease
on their backs. This group was treated by the same protocol
as Group I and was evaluated three times daily by a
dermatologist.

Summary of the Results

Group I: By the tenth day of treatment the psoriatic plates
and inflamed areas of the treated skin started to heal. By the
twentieth day the Auspitz sign had disappeared on all
patients. By day 27 the psoriatic plates present in the
diseased skin of all patients had disappeared. By day 35 the
skin on all patients appeared to be healed and the pigmen-
tation process of the skin had been initiated.

Group II: By the twentieth day of treatment, the healing
process on all patients had commenced as evidenced by the
reduction of psoriatic plates and appearance of new tissue.
By day 28 the diseased areas were of smaller sizes and the
Auspitz sign was no longer visible. By day 30, the Koebner
phenomenon had disappeared on all patients. By day 35, the
psoriatic plates were barely visible on all patients.

Continued observation of both groups showed no further
changes in their condition after treatment was halted.

The above tests demonstrate that topical application of
tetrasilver tetroxide to the affected skin areas of psoriasis
sufferers effectively heals and/or controls this disease.

EXAMPLE 12

Twelve Caucasian patients between the ages of 45 to 65
presented with infected bleeding skin ulcers associated with
diagnosed Rabdomiosarcoma, which had persisted up to 7
months prior to treatment. The patients were divided into
two groups:

Group I: Seven patients where the ulcerated lesions
averaged 9 cm long and 12 cm in diameter.

Group II: Five patients where the ulcerated lesions were
greater than 12 cmx2 cm.

The patients of each group were treated by the application
to affected skin areas of about 200 mg of petroleum jelly
containing 3 wt % of tetrasilver tetroxide three times daily
over a period of 30 days.

All patients were examined daily by a dermatologist to
evaluate the effectiveness of the treatment.

Summary of Results

Group I: All patients experienced a commencement of
healing of the ulcers by day 27 from the start of the
treatment. By day 30 the ulcers were dry. On day 40 new
cells had replaced infected cells. By day 45 ulcers and sores
were no longer visible and new tissue was evident replacing,
the ulcerated tissue.

Group II: All patients showed a commencement of the
healing of the ulcers by day 28 from the start of the
treatment. By day 40 the ulcers had almost disappeared and
a biopsy confirmed that 80% of the diseased tissue had been
replaced with healthy tissue. From a clinical standpoint, the
ulcers were no longer visible.

The tests demonstrate that the topical application of
tetrasilver tetroxide is effective in curing infections and

20

30

40

50

60

8

healing skin ulcers associated with Rabdomiosarcoma, and
without side effects.

Based on all of the test data described above, the healing,
mechanism associated with the use of tetrasilver tetroxide to
treat and cure at least some skin diseases appears to be more
than simply the killing of pathogens and curing infections
which tend to aggravate disease and retard the natural
healing process. The data indicate that healing is brought
about even in cases where no abnormal bacteria counts or
infection is evident. This suggests that tetrasilver tetroxide
perhaps also acts against autoantibodies which trigger
autoimmune reactions associated with diseased tissue.

What is claimed is:

1. A method for treating dermatological skin disease
comprising applying a composition comprising a therapeu-
tically effective amount of tetrasilver tetoxide directly to the
affected skin of a patient in need of treatment, said compo-
sition being free of added oxidizing agent, wherein the
dermatological skin disease is selected from the group
consisting of eczema, psoriasis, dermatitis, ulcers, shingles,
rashes, bedsores, cold sores, blisters, boils, herpes, acne,
pimples, warts, and a combination thereof.

2. The method of claim 1, wherein the tetrasilver tetoxide
is dispersed in a carrier medium at a concentration of from
about 50 to 250,000 wt PPM, based on the weight of said
carrier medium.

3. The method of claim 2 wherein said concentration is
from about 400 to 50,000 PPM.

4. The method of claim 2 wherein said carrier medium
comprises petroleum jelly.

5. The method of claim 1,
includes cold sores.

6. The method of claim 1.
includes herpes.

7. The method of claim 1,
includes shingles.

8. The method of claim 1,
includes acne.

9. The method of claim 1,
includes psoriasis.

10. The method of claim 1,
includes dermatitis.

11. The method of claim 1, wherein
includes disease-induced skin ulcers.

12. The method of claim 1, wherein
includes eczema.

13. The method of claim 1, wherein said tetrasilver
tetroxide is applied in powered form.

14. The method of claim 1, wherein said composition is
applied to the skin at a dosage level of from about 10 to 500
mg per cm? of skin surface.

15. The method of claim
includes warts.

16. The method of claim
includes pimples.

17. The method of claim
includes blisters.

18. The method of claim
includes bedsores.

19. The method of claim
includes rashes.

20. The method of claim 1, wherein said composition is
applied in non-sprayable form.

wherein said skin disease

wherein said skin disease

wherein said skin disease

wherein said skin disease

wherein said skin disease

wherein said skin disease

said skin disease

said skin disease

1, wherein said skin disease

1, wherein said skin disease

1, wherein said skin disease

1, wherein said skin disease

1, wherein said skin disease